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Background: Human immunodeficiency virus (HIV) infection with advanced immunosup-
pression predisposes to cryptococcal meningitis (CM). We describe the incidence, clinical 
presentation, and outcome of CM in HIV-infected individuals during the highly active antiret-
roviral therapy (HAART) era.
Methods: A nationwide, population-based cohort of HIV-infected individuals was used to 
estimate incidence and mortality of CM including risk factors. A description of neurological 
symptoms of CM at presentation and follow-up in the study period 1995–2014 was included 
in this study.
Results: Among 6,351 HIV-infected individuals, 40 were diagnosed with CM. The incidence 
rates were 3.7, 1.8, and 0.3 per 1000 person-years at risk in 1995–1996, 1997–1999, and 
2000–2014, respectively. Initiation of HAART was associated with decreased risk of acquir-
ing CM [incidence rate ratio (IRR), 0.1 (95% CI, 0.05–0.22)]. African origin was associated 
with increased risk of CM [IRR, 2.05 (95% CI, 1.00–4.20)]. The main signs and symptoms at 
presentation were headache, cognitive deficits, fever, neck stiffness, nausea, and vomiting. All 
individuals diagnosed with CM had a CD4+ cell count <200 cells/µl [median 26; interquartile 
range (IQR), 10–50)]. Overall, mortality following CM was high and mortality in the first 4 
months has not changed substantially over time. However, individuals who survived generally 
had a favorable prognosis, with 86% (18/21) returning to the pre-CM level of activity.
Conclusion: The incidence of HIV-associated CM has decreased substantially after the intro-
duction of HAART. To further decrease CM incidence and associated mortality, early HIV 
diagnosis and HAART initiation seems crucial.
Keywords: cryptococcal meningitis, highly active antiretroviral therapy, HIV
Background
Cryptococcal meningitis (CM) is caused by the encapsulated yeast Cryptococcus (C.) 
neoformans and is generally diagnosed in individuals with cellular immune deficien-
cies, such as human immunodeficiency virus (HIV)/acquired immune deficiency 
syndrome (AIDS).1 CM is the most common cause of meningitis in some areas of 
sub-Saharan Africa, where the occurrence of CM is the highest in the world.2 An 
estimated one million new cases are diagnosed each year and, worldwide, the disease 
causes >600,000 deaths yearly.3 The incidence of HIV-associated CM is lowest in 
Western countries and has declined considerably in North America and Western 
Europe after the introduction of highly active antiretroviral therapy (HAART).4–9 
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Incidence rates ranged from 2.5/1000 person-years at risk 
(PYR) in the pre-HAART era to 1.5/1000 PYR in the post-
HAART era.10
There has been a general decrease in mortality in HIV-
infected individuals in Denmark during the HAART era.11 
The substantial reduction in HIV-associated mortality due 
to HAART resulted in a notable shift in causes of death 
among HIV-infected individuals.12 HIV-infected individuals 
are more vulnerable to age-, disease-, and/or treatment-
related morbidities.13,14 The main focus in HIV care in the 
post-HAART era has been HAART-related problems such 
as toxicity, drug–drug interactions, and antiretroviral drug 
resistance.15
The use of HAART in high-income countries has 
improved the long-term survival of HIV-infected individu-
als with CM, but the mortality rate remains high during 
the first 3 months of CM.16 This highlights the importance 
of diagnosing HIV-infected individuals during an early 
stage, before they develop severe immunodeficiency, to 
avoid AIDS-associated diseases such as CM. To prevent 
and control CM in the future, it is imperative to gain insight 
into the epidemiology of CM. We used a nationwide, 
population-based cohort of HIV-infected individuals to 
determine incidence, clinical presentation, and prognosis 
of CM. Furthermore, we collected data on choice of treat-
ment regimens of CM.
Methods
study design
This nationwide cohort study is divided into two parts. In 
the first part of the study, we estimated the incidence of 
CM in a cohort of HIV-infected individuals in the period 
1995–2014. In the second part of the study, the study popu-
lation comprised HIV-infected individuals diagnosed with 
CM, and the outcomes were neurological symptoms and 
mortality. We used a study design that has been described 
previously.17
setting
On December 31, 2014, Denmark had a population of 
5.6 million citizens and the estimated prevalence of HIV-
infection in the adult population was 0.1%.18 Antiretroviral 
treatment is provided free of charge in Denmark to all HIV-
infected individuals in one of the country’s eight specialized 
HIV-care centers. HIV-infected individuals are seen on an 
outpatient basis at intended intervals of 12–24 weeks. The 
national criteria for initiating HAART has been described 
elsewhere.19
Data extraction
Participants were included from the Danish HIV Cohort 
Study (DHCS) – a prospective study that includes all HIV-
infected individuals ≥16 years since January 1, 1995. Data 
include demographics, date of HIV diagnosis, AIDS-defining 
events, antiretroviral treatment, CD4+ cell counts, viral loads, 
and so on. Individuals are consecutively enrolled and data 
are updated annually. All Danish citizens are provided with a 
unique 10-digit personal identification number (PIN) at birth 
or immigration, which prevents multiple registrations in the 
DHCS. The DHCS has been described in detail previously.19
study population
All HIV–1 infected individuals who 1) were registered in 
the DHCS prior to December 31, 2014; 2) lived in Denmark 
at study inclusion; and 3) had been assigned a PIN were 
included in this study.
Outcome and statistical analysis
Part 1
In the first part of the study, the outcome was time to first 
diagnosis of CM. A diagnosis of CM was defined as detection 
of C. neoformans in the cerebrospinal fluid (CSF) by micros-
copy, culture, or antigen-test; the test was performed at Statens 
Serum Institut, were they used a latex agglutination test.20
The PYR was calculated from HIV diagnosis or from 
January 1, 1995, whichever came last until a diagnosis of CM, 
death, emigration, or December 31, 2014, whichever came 
first. Incidence rates (IRs) for CM and 95% confidence inter-
vals (95% CI) were calculated for the periods 1995–1996, 
1997–1999, and 2000–2014, which corresponds to the pre-, 
early-, and late HAART periods, data from previous studies 
have indicated that the use of HAART has changed substan-
tially between these time periods.21 For the individuals that 
received HAART during the study period, we calculated IRs 
from initiation of HAART to CM.
In addition to this, we stratified the analyses based on 
gender and origin (African and non-African).
Part 2
In the second part of the study, outcome measures were 
neurological symptoms and mortality among HIV-infected 
individuals with CM. Information about laboratory results, 
treatment, and neurological symptoms at the presentation of 
CM were extracted from patient records.
Individuals diagnosed with CM were followed for a total 
of 3 years or until death, emigration, or December 31, 2014 
whichever came first.
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Neurological symptoms were estimated 4 months and 3 
years after CM diagnosis. Neurological status was defined 
as deteriorated, unchanged, better, or resolved compared to 
their pre-CM status.
Poisson regression analysis was used to calculate inci-
dence rate ratios (IRRs) as estimates of the impact of risk 
factors on incidence of CM in the HIV-infected population. 
Multivariate models included the following covariates: 
gender, age (≤40 years vs >40 years), origin (African vs 
non-African), route of transmission [injection drug user vs 
heterosexual vs men who have sex with men (MSM)], and 
year of CM diagnosis (before vs after January 1, 1997).
Statistical analyses were undertaken with Stata statistical 
software: Release 11 (StataCorp. 2009, StataCorp LP, College 
Station, TX, USA).
Ethics statement
The study was approved by the Danish Data Protection 
Agency (journal no. 2008-41-1781). According to Danish 
legislations individual consent is not required to perform 
register based studies.
Results
During screening, 6,351 HIV-infected individuals fulfilled 
the study inclusion criteria. Of these, 2,015 (32%) individuals 
were diagnosed with HIV before January 1, 1995; 1,115 (18%) 
individuals died and 138 (2%) emigrated during follow-up. 
A total of 4,829 (76%) were men, 2,952 (46%) were MSM, 
611 (10%) were injection drug users, and 4,970 (78%) were 
Caucasian. The median age at study inclusion was 35.0 years 
[interquartile range (IQR), 28.5–43.1 years; Table 1].
Part 1
incidence of CM
Forty individuals were diagnosed with CM during the study 
period; 15 were diagnosed with CM between 1995 and 1996, 
8 between 1997 and 1999, and 17 in the years 2000–2014.
The overall incidence decreased from the pre-HAART 
era [IR 3.7/1000 PYR (95% CI, 2.2–6.1)] to the early- [IR 
1.8/1000 PYR (95% CI, 0.9–3.6)] and late-HAART era [IR 
0.3/1000 PYR (95% CI, 0.2–0.5)] (Table 2).
In individuals in whom HAART was initiated, the inci-
dence of CM was 0.2/1000 PYR (95% CI, 0.1–0.3). The 
IR was 0.5/1000 PYR (95% CI, 0.3–0.7) for individuals of 
non-African origin and 1.1/1000 PYR (95% CI, 0.6–2.0) for 
individuals of African origin.
HAART was associated with a substantial reduction in 
risk of acquiring CM [IRR 0.1 (95% CI, 0.05–0.22)]. When 
we adjusted for potential confounders (gender, age, origin, 
and route of transmission), the impact of HAART on the 
risk of CM did not change substantially [IRR, 0.09 (95% CI, 
0.05–0.19)]. African origin was associated with increased risk 
of CM [IRR, 2.05 (95% CI, 1.00–4.20); Table 2].
Part 2
Characteristics
Characteristics of the HIV-infected individuals diagnosed 
with CM are summarized in Table 1. All individuals had 
late-stage HIV disease at CM presentation with a CD4+ cell 
count <200 cells/µl [median 26 (IQR, 10–50)]. The median 
viral load at diagnosis was 4.8 (IQR, 3.0–5.4) log
10 
copies/mL. 
Thirty-three percent (13/40) were diagnosed with AIDS prior 
to CM. Thirty-three percent (13/40) were late presenters – that 
is, they were diagnosed with CM at HIV-diagnosis ± 30 days.
The median time from HIV diagnosis to CM was 2.24 
years (IQR, 0.02–6.55). Seventy-three percent (29/40) of CM 
individuals were men, 40% (16/40) were MSM, and 53% 
(21/40) were heterosexual. The median age at CM diagnosis 
was 38.0 years (IQR, 32.3–44.3).
Diagnostic methods
Patient records and, thereby, clinical and paraclinical data 
were missing for 3 out of 40 individuals with CM. Diagnostic 
results and neurological symptoms are, therefore, only avail-
able for a maximum of 37 HIV-infected individuals with CM.
Among those tested, 85% (28/33) tested positive for 
cryptococcal antigen in CSF and/or blood (Table 3); 70% 
(23/33) were diagnosed by culture for C. neoformans in CSF 
or blood, and three individuals had a positive blood culture 
only. Fifty-nine percent (16/27) were diagnosed by micros-
copy of the CSF for C. neoformans and 14 of those had a 
positive India ink report. The diagnosis was mainly based on 
a combination of different diagnostic methods.
Seventy-eight percent (29/37) presented with fever and 
80% (24/30) had elevated sedimentation rate or C-reactive 
protein (CRP) level. In contrast, only few individuals had 
leukocytosis in peripheral blood. CSF pleocytosis was seen 
in 57% (20/35). Seventy-five percent (15/20) with CSF pleo-
cytosis had leukocyte differentiation, with a predominance of 
lymphocytes in 10 out of 15 individuals, whereas neutrophils 
predominated in the latter five individuals. Seventy-seven 
percent (27/35) had elevated CSF protein levels. The median 
CSF glucose level was 2.25 (IQR, 1.1–3) mmol/L.
neurological symptoms
The most frequent signs and symptoms were fever, headache, 
nausea, and vomiting cognitive deficits and neck stiffness. 
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Other neurological signs and symptoms such as coordination 
disturbance, speech disturbance, visual impairment, facial 
palsy, limb paresis, seizures, photophobia, and papilledema 
occurred less frequently (Table 4). Only two individuals pre-
sented with a Glasgow Coma Scale <9, and these individuals 
were admitted to the intensive care units at presentation of 
CM (Table 3).
After 4 months of follow-up, the main symptoms were 
nausea, vomiting, and headache. Eighty-one percent (13/16) 
had an improvement of symptoms, and 62% (10/16) recon-
stituted to their pre-CM level of activity. Two individuals 
showed progression of neurological symptoms and one had 
the same symptoms as at the onset of CM.
Within 3 years of follow-up, 86% (18/21) had returned to 
their pre-CM level of activity (Table 4). Table 1 shows anti-
fungal therapy and reasons for stopping maintenance therapy.
Mortality
Fifty-three percent (21/40) of individuals diagnosed with CM 
died during the study period; in eight of these cases, death 
was due to CM. Ten individuals died due to other HIV-related 
causes such as progressive multifocal leukoencephalopathy 
Table 1 Characteristics of all hiV-infected individuals and hiV-infected individuals with CM including data on treatment
Characteristics/treatment HIV-infected individuals CM individuals 
All
(n=6351)
(n=40)
age at hiV/CM diagnosis, median (iQr), years 35.0 (28.5–43.1) 38.0 (32.3–44.3)
Total PYr 66,548 63
Emigrated during study period 138 (2) 2 (5)
Died during study period 1115 (18) 21 (53)
Male 4829 (76) 29 (73)
Caucasian 4970 (78) 25 (63)
Country of birth
Denmark 4398 (69) 23 (58)
Europe 462 (7) 2 (5)
africa 864 (14) 10 (25)
asia 332 (5) 5 (13)
Other/Unknown 257 (4) 0 (0)
route of transmission
MsM 2952 (46) 16 (40)
heterosexual 2371 (37) 21 (53)
injection drug use 611 (10) 1 (3)
Other/Unknown 370 (6) 2 (5)
Diagnosed with hiV before 1995 2015 (32) 15 (38)
hiV rna level at hiV/CM diagnosis, median (iQr), log10 copies/ml 4.8 (4.13–5.4) 4.8 (3.0–5.4)
CD4+ cell count at hiV/CM diagnosis, median (iQr), cells/µl 310 (113–514) 26 (10–50)
CD4+ cell count <200 cells/µl at CM diagnosis – 40 (100)
aiDs diagnosis before CM diagnosis – 13 (33)
hiV diagnosis before CM diagnosis – 27 (68)
hiV diagnosis at the time of CM diagnosis – 13 (33)
interval between hiV diagnosis and CM, median (iQr), years – 2.24 (0.02–6.55)
Treatment of individuals with CMa
amphotericin B – 32 (86)
Fluconazole – 15 (40)
Voriconazole – 1 (3)
Flucytosine – 24 (65)
itraconazole – 1 (3)
steroids – 6 (16)
haarT – 30 (75)
Maintenance therapy with fluconazole – 30 (81)
Years on fluconazole prophylaxis, median (IQR) years – 1.94 (0.50–4.55)
reason for stopping antifungal prophylaxisb
immunological restoration – 10 (27)
Other reason – 3 (8)
Death – 11 (30)
Emigration – 1 (3)
Note: Data presented as n (%) of individuals, unless otherwise indicated. aData on 37 individuals. bThree individuals were still treated with antifungal prophylaxis when the 
study ended.
Abbreviations: CM, cryptococcal meningitis; iQr, interquartile range; PYr, person-years at risk; MsM, men who have sex with men; haarT, highly active antiretroviral therapy.
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(PML), Kaposi sarcoma, lymphoma, anal cancer, bacterial 
infection, and pneumonia. One individual died due to traumatic 
brain injury and, in two cases, the cause of death was unknown.
Twelve individuals died within the first 4 months of 
follow-up, and two additional individuals died within the 
subsequent 3-year period.
Discussion
This nationwide, population-based cohort study demonstrates 
that both incidence and mortality of CM among HIV-infected 
individuals in Denmark have decreased dramatically during 
the last 20 years (1995–2014).
Furthermore, CM was observed in individuals with 
advanced HIV disease and severe immunodeficiency, docu-
mented by a low median CD4+ cell count and a high viral 
load. As in findings from other studies,22 the most frequent 
signs and symptoms were fever, headache, nausea and 
vomiting, cognitive deficits, and neck stiffness. Our study 
showed that the sensitivity of CSF pleocytosis in individuals 
diagnosed with CM was 57%. Other observations made by a 
French study found that 25% of all CM individuals in France 
had a normal CSF cell count.23 The absence of pronounced 
inflammation could be regarded as an argument against 
CNS infection; however, our findings indicate that a normal 
CSF cell count does not exclude a CM diagnosis. Other 
European studies found that cryptococcal antigen testing in 
HIV-infected individuals with low immunity might represent 
a strategy to expedite the diagnosis of CM.24 However, cryp-
tococcal antigen testing in CSF and/or blood had a sensitivity 
of 85% in our study.
A low CD4+ cell count was the strongest predictor for 
being diagnosed with CM. It is most likely that the observed 
reduction in CM incidence among HIV-infected individu-
als is due to improved management of HIV by increased 
use of HAART and decreased antiretroviral resistance in 
 Denmark.25 These findings suggest that early detection of 
HIV followed by HAART initiation is essential to avoid 
severe  immunodeficiency and, thereby, life-threatening 
HIV-associated diseases such as CM. The main focus in the 
management of CM should be the prophylactic effect of 
maintaining a high CD4+ cell count. Our study shows that 
33% of all CM individuals during the study period presented 
for care with an AIDS-defining event. If these late present-
ers were diagnosed before severe immunodeficiency and 
HAART was initiated shortly thereafter, these cases could 
probably be avoided.
Table 2 incidence rates and incidence rate ratios of CM in hiV-infected individuals
Category PYR, n CM events, n IR, per 1,000 PYR (95% CI) IRR (95% CI)
Observation period
1995–1996 4,058 15 3.7 (2.2–6.1) 1 (ref.)
1997–1999 4,441 8 1.8 (0.9–3.6) 0.49 (0.21–1.15)
2000–2014 58,049 17 0.3 (0.2–0.5) 0.08 (0.04–0.16)
gender
Men 49,459 29 0.6 (0.4–0.8) 0.91 (0.46–1.82)
Women 17,088 11 0.6 (0.4–1.2) 1.10 (0.55–2.20)
Origin
non-african 46,529 23 0.5 (0.3–0.7) 1 (ref)
african 9,290 10 1.1 (0.6–2.0) 2.05 (1.00–4.20)
haarT
receiving haarT 50,604 9 0.2 (0.1–0.3) 0.1 (0.05–0.22)
Abbreviations: IR, incidence rate; IRR, incidence rate ratio; CM, cryptococcal meningitis; CI, confidence interval; HAART, highly active antiretroviral therapy; PYR, person-
years at risk.
Table 3 Clinical and paraclinical data at presentation in 37 hiV-
infected individuals with CM and results of diagnostic tests
Category, parameter
Clinical and paraclinical signs at  
presentation
Proportion
Number with 
positive test/
number  
tested (%)
Positive results of diagnostic tests for CM
C. neoformans in CsF or blood by culture 23/33 (70)
C. neoformans in CsF by microscopy 16/27 (59)
Cryptococcal antigen in CsF and/or blood 28/33 (85)
Fever >37.5°C 29/37 (78)
Fever >38.0°C 26/37 (70)
Elevated sedimentation rate or CrP level 24/30 (80)
leukocytosis in peripheral blood (>9×109 cells/l) 2/36 (6)
CsF pleocytosis (>10 cells/µl) 20/35 (57)
Elevated CsF protein level (>0.5 g/l) 27/35 (77)
CsF glucose level median (iQr) 2.25 (1.1–3)a
glasgow Coma scale (range 0–15)
severely impaired (gCs <9) 2/37 (5)
Moderately impaired (gCs 9–12) 1/37 (3)
Mildly or not impaired (gCs >12) 34/37 (92)
Note: aFive individuals had missing data on CsF glucose level measurement.
Abbreviations: CM, cryptococcal meningitis; CSF, cerebrospinal fluid; IQR, 
interquartile range; CrP, C-reactive protein; gCs, glasgow Coma scale. 
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African origin was associated with a higher incidence 
of CM, which corresponds well with the findings of other 
 studies.7,26,27 CM is a subacute infection, with a long subclini-
cal phase.28 The increased risk in individuals of African origin 
most likely reflects that immigrants import the disease in the 
subclinical phase that then develops to manifest disease after 
arriving in Denmark.
We generally observed high mortality following HIV- 
associated CM, and were unable to identify a reduction in mor-
tality of HIV-associated CM over time; specifically, the mortality 
in the first 4 months did not seem to have changed substantially. 
However, our statistical power to show a difference was small.
A previous study in Denmark described the outcome of CM 
in HIV-infected individuals treated at two university hospitals in 
Copenhagen between 1988 and 2008.29 In accordance with our 
study, they found that long-term survival after CM improved 
significantly with the use of HAART. Our study shows that most 
survivors recovered with only few neurological complications. 
This emphasizes the importance of early detection of CM and 
initiation of aggressive therapy including HAART. However, to 
further decrease CM incidence and associated mortality, early 
HIV diagnosis and HAART initiation seems crucial.
To our knowledge, this is the first study to present 
nationwide population-based data on the incidence of CM 
in  HIV-infected individuals as well as clinical presentation 
and outcome of CM during the HAART era in Denmark. 
Our study’s major strengths are the nationwide, population-
based design, the long and nearly complete follow-up, and 
completeness of data.
Our study has some weaknesses. Neurological symptoms 
were examined retrospectively from patient records. Conse-
quently, the degree of neurological symptoms at presentation 
of CM and sequelae after the diagnosis of CM may have been 
even worse than what we have observed. Our study population 
predominantly included Caucasians (78%) and our results 
could, therefore, not be generalized to geographical regions 
such as Africa and Asia.
In conclusion, this study shows that the overall inci-
dence and mortality of CM decreased from the pre- to the 
late-HAART era. Although CM is a very rare disease in 
Denmark, it could be connected to an initial manifestation 
of HIV infection or AIDS and should still be suspected in all 
HIV-infected individuals with low CD4+ cell count presenting 
with neurological symptoms, headache, and fever.
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Table 4 neurological symptoms at primary presentation in 37 hiV-infected individuals with CM and after 4 months and 3 years after 
CM
Category, parameter Disease presentation 
(n=37)
4-month follow-up
(n=16)
3-year follow-up
(n=21)
neurological symptoms
Cognitive deficits 15 (41) 1 (6) 1 (5)
Coordination disturbance 7 (19) 2 (12) 0 (0)
speech disturbance 3 (8) 2 (12) 0 (0)
Visual impairment 5 (13) 1 (6) 0 (0)
Facial palsy 1 (3) 0 (0) 0 (0)
limb paresis 4 (11) 2 (12) 0 (0)
sensory affection 0 (0) 0 (0) 0 (0)
seizures 4 (11) 0 (0) 0 (0)
need help in everyday life 2 (5) 3 (19) 0 (0)
headache 27 (73) 7 (44) 0 (0)
Fever 29 (78) 2 (12) 0 (0)
nausea and vomiting 16 (43) 4 (25) 0 (0)
neck stiffness 12 (32) 0 (0) 0 (0)
Photophobia 3 (8) 0 (0) 0 (0)
Papilledema 2 (5) 0 (0) 0 (0)
status at follow-up
Progression of neurological symptoms – 2 (12) 0 (0)
Unchanged neurological symptoms – 1 (6) 0 (0)
improvement of neurological symptoms – 13 (81) 1 (5)
return to pre-CM level of activity – 10 (62) 18 (86)
Note: Data presented as n (%) of individuals.
Abbreviation: CM, cryptococcal meningitis.
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hiV-1-associated cryptococcal meningitis
Study centers of the Danish HIV Cohort Study: Depart-
ments of Infectious Diseases at Copenhagen University 
 Hospitals, Rigshospitalet (J Gerstoft, N Obel) and Hvidovre 
(G Kronborg), Odense University Hospital (C Pedersen), 
 Aarhus University Hospitals, Skejby (CS Larsen) and 
 Aalborg (G Pedersen), Herning Hospital (R Mohey), Hillerød 
Hospital (L Nielsen), and Kolding Hospital (J Jensen).
Disclosures
NO has received research funding from Roche, Bristol-Myers 
Squibb, Merck Sharp & Dohme, GlaxoSmithKline, Abbott, 
Boehringer Ingelheim, Janssen-Cilag, and Swedish Orphan. 
MGA has received research funding from the research board 
of Copenhagen University Hospital, Rigshospitalet, and from 
the Bjørn Astrups fund, and has received travel grants from 
GSK and Janssen.
The sponsors had no role in the design, conduct, or analy-
sis of the study nor in the decision to publish the manuscript. 
The authors report no other conflicts of interest in this work.
References
 1  Bicanic T, Harrison TS. Cryptococcal meningitis. Br Med Bull. 
2005;72:99–118.
 2  Veltman JA, Bristow CC, Klausner JD. Meningitis in HIV-positive 
patients in sub-Saharan Africa: a review. J Int AIDS Soc. 2014;17:19184.
 3  Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas 
PG, Chiller TM. Estimation of the current global burden of cryp-
tococcal meningitis among persons living with HIV/AIDS. AIDS. 
2009;23(4):525–530.
 4  Dromer F, Mathoulin-Pélissier S, Fontanet A, Ronin O, Dupont B, 
Lortholary O; French Cryptococcosis Study Group. Epidemiology of 
HIV-associated cryptococcosis in France (1985–2001): comparison of 
the pre- and post- HAART eras. AIDS. 2004;18(3):555–562.
 5  Antinori S, Ridolfo A, Fasan M, et al. AIDS-associated cryptococcosis: 
a comparison of epidemiology, clinical features and outcome in the 
pre- and post-HAART eras. Experience of a single centre in Italy. HIV 
Med. 2009;10(1):6–11.
 6  van Elden LJ, Walenkamp AM, Lipovsky MM, et al. Declining number 
of patients with cryptococcosis in the Netherlands in the era of highly 
active antiretroviral therapy. AIDS. 2000;14(17):2787–2788.
 7  Mirza SA, Phelan M, Rimland D, et al. The changing epidemiology of 
cryptococcosis: an update from population-based active surveillance in 2 
large metropolitan areas, 1992–2000. Clin Infect Dis. 2003;36(6):789–794.
 8  Pyrgos V, Seitz AE, Steiner CA, Prevots DR, Williamson PR. Epide-
miology of cryptococcal meningitis in the US: 1997–2009. PLoS One. 
2013;8(2):e56269.
 9  d’Arminio Monforte A, Cinque P, Mocroft A, et al; EuroSIDA Study 
Group. Changing incidence of central nervous system diseases in the 
EuroSIDA cohort. Ann Neurol. 2004;55(3):320–328.
10  Sacktor N, Lyles RH, Skolasky R, et al; Multicenter AIDS Cohort Study. 
HIV-associated neurologic disease incidence changes: Multicenter AIDS 
Cohort Study, 1990–1998. Neurology. 2001;56(2):257–260.
11  Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and 
without HIV infection in Denmark, 1995–2005. Ann Intern Med. 
2007;146(2):87–95.
12  Zwahlen M, Lundgren JD. Commentary: death in the era of potent 
antiretroviral therapy: shifting causes, new challenges. Int J Epidemiol. 
2005;34(1):130–131.
13  Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, 
and non-AIDS related morbidity. BMJ. 2009;338:a3172.
14  Hasse B, Ledergerber B, Furrer H, et al; Swiss HIV Cohort Study. 
Morbidity and aging in HIV-infected persons: the Swiss HIV Cohort 
Study. Clin Infect Dis. 2011;53(11):1130–1139.
15  Marzolini C, Elzi L, Gibbons S, et al; Swiss HIV Cohort Study. 
Prevalence of comedications and effect of potential drug-drug inter-
actions in the Swiss HIV Cohort Study. Antivir Ther. 2010;15(3): 
413–423.
16  Lortholary O, Poizat G, Zeller V, et al. Long-term outcome of AIDS-
associated cryptococcosis in the era of combination antiretroviral 
therapy. AIDS. 2006;20(17):2183–2191.
17  Engsig FN, Hansen AB, Omland LH, et al. Incidence, clinical presen-
tation, and outcome of progressive multifocal leukoencephalopathy in 
HIV-infected patients during the highly active antiretroviral therapy era: 
a nationwide cohort study. J Infect Dis. 2009;199(1):77–83.
18  Statistics Denmark [homepage on the Internet] Population and elections. 
Available from: http://www.statistikbanken.dk. Accessed February 16, 
2017.
19  Omland LH, Ahlström MG, Obel N. Cohort profile update: the Danish 
HIV Cohort Study (DHCS). Int J Epidemiol. 2014;43(6):1769–9e.
20  Cryptococcus Antigen Testing [webpage] Available from: http://www.
ssi.dk/Diagnostik/DiagnostiskHaandbog/0-99/058.aspx. Accessed 
February 16, 2017.
21  Helleberg M, Häggblom A, Sönnerborg A, Obel N. HIV care in the 
Swedish-Danish HIV cohort 1995–2010, closing the gaps. PLoS One. 
2013;8(8): e72257.
22  Seboxa T, Anemu S, Assefa A, Asefa A, Diro E. Cryptococcal meningitis 
in patients with acquired immuno-deficiency syndrome in preHAART 
era at Gondar College of Medical Sciences Hospital north-west Ethiopia. 
Ethiop Med J. 2010;48(3):237–241.
23  Darras-joly C, Chevret S, Wolff M, et al. Cryptococcus neoformans 
infection in France: epidemiologic features and early prognostic param-
eters for 76 patients who were infected with human immunodeficiency 
virus. Clin Infect Dis. 1996;23(2):369–376.
24  Katchanov J, von Kleist M, Arastéh K, Stocker H. “Time-to-
amphotericin B” in cryptococcal meningitis in a European low-
prevalence setting: analysis of diagnostic delays. QJM. 2014;107(10): 
799–803.
25  Lohse N, Obel N, Kronborg G, et al. Declining risk of triple-class 
antiretroviral drug failure in Danish HIV-infected individuals. AIDS. 
2005;19(8):815–822.
26  Jarvis JN, Harrison TS. HIV-associated cryptococcal meningitis. AIDS. 
2007;21(16):2119–2129.
27  Kisenge PR, Hawkins AT, Maro VP, et al. Low CD4 count plus coma pre-
dicts cryptococcal meningitis in Tanzania. BMC Infect Dis. 2007;7:39.
28  Meya DB, Manabe YC, Castelnuovo B, et al. Cost-effectiveness 
of serum cryptococcal antigen screening to prevent deaths among 
HIV-infected persons with a CD4+ cell count < or =100 cells/microL 
who start HIV therapy in resource-limited settings. Clin Infect Dis. 
2010;51(4):448–455.
29  Mathiesen IHM, Knudsen JD, Gerstoft J, Cowan S, Benfield T. Outcome 
of HIV-1-associated cryptococcal meningitis, Denmark 1988–2008. 
Scand J Infect Dis. 2012;44(3):197–200.
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
87
.1
74
 o
n 
22
-A
ug
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2017:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Clinical Epidemiology
Publish your work in this journal
Submit your manuscript here: https://www.dovepress.com/clinical-epidemiology-journal
Clinical Epidemiology is an international, peer-reviewed, open access, 
online journal focusing on disease and drug epidemiology, identifica-
tion of risk factors and screening procedures to develop optimal pre-
ventative initiatives and programs. Specific topics include: diagnosis, 
prognosis, treatment, screening, prevention, risk factor modification, 
systematic reviews, risk and safety of medical interventions, epidemiol-
ogy and biostatistical methods, and evaluation of guidelines, translational 
medicine, health policies and economic evaluations. The manuscript 
management system is completely online and includes a very quick 
and fair peer-review system, which is all easy to use.
Dovepress
392
Touma et al
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
87
.1
74
 o
n 
22
-A
ug
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
